Related Experiment Video
Updated: Jun 19, 2026

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
Published on: July 5, 2021
Absence of pathognomonic or inflammatory patterns in cardiac biopsies from patients with Brugada syndrome
Sven Zumhagen1, Tilmann Spieker, Julia Rolinck
1Department of Cardiology and Angiology, Hospital of the University of Münster, Münster, Germany.
Insights
Brugada syndrome (BrS) patients often show moderate, uncharacteristic right ventricular abnormalities on imaging and biopsy. Few patients had significant histopathologic changes, suggesting diverse causes for the Brugada ECG phenotype.
Area of Science:
- Cardiology
- Genetics
- Pathology
Background:
- Brugada syndrome (BrS) presents with specific ECG changes and is linked to ion channel gene mutations.
- BrS can cause conduction disturbances and ventricular fibrillation.
- The underlying cause of BrS, whether purely electrical or involving right ventricular (RV) histopathology, is debated.
Purpose of the Study:
- To investigate histopathologic abnormalities in the RV of BrS patients.
- To correlate histopathologic findings with clinical, genetic, and imaging data.
Main Methods:
- Retrospective analysis of RV biopsy samples from 21 BrS patients.
- Evaluation for hypertrophy, fibrosis, inflammation, and fatty tissue.
- Correlative analysis with clinical, genetic, and imaging data (angiography, echocardiography, cardiac MRI).
Main Results:
- Most myocardial biopsies showed moderate, uncharacteristic abnormalities.
- Predominant fatty tissue was found in 19% of RV myocardium.
- No evidence of inflammatory tissue changes or myocarditis was detected.
Conclusions:
- Moderate cardiac abnormalities are detectable in BrS patients but are uncharacteristic.
- Arrhythmogenic RV cardiomyopathy and overt myocarditis were not observed.
- Specific RV histopathologic changes were rare, suggesting multifactorial causes for the Brugada ECG phenotype.
Background:
Brugada syndrome (BrS) is characterized by the presence of coved ST-segment elevations in the right precordial leads (so-called type I ECG) and additional clinical features. Caused by cardiac ion channel gene mutations, BrS may be associated with ventricular and atrial conduction disturbances as well as ventricular fibrillation. Recent studies have discussed whether BrS is merely a primary electric disorder or whether inflammatory or other histopathologic abnormalities in the right ventricle (RV) underlie the ECG phenotype.
Methods And Results:
We retrospectively analyzed BrS biopsy samples from 21 unrelated patients for histopathologic abnormalities (hypertrophy, fibrosis, inflammation, fatty tissue) together with the patients' clinical, genetic, and imaging data. Eleven patients (52%) had normal RV imaging (by angiography, echocardiography, or cardiac MRI). Results of myocardial biopsies were normal in 3 patients (14%) and revealed mostly moderate abnormalities in the others. Four patients (19%) had predominant fatty tissue in the RV myocardium. Using immunohistochemistry and conventional tissue staining, we could not detect inflammatory tissue changes, an observation compatible with the clinical absence of signs for myocarditis.
Conclusions:
Imaging and histopathologic evaluation may detect moderate but uncharacteristic cardiac abnormalities in patients with BrS. None of the patients had arrhythmogenic RV cardiomyopathy or overt myocarditis. Only in a small subset did predominant histopathologic abnormalities in the biopsy samples of the RV outflow tract occur that could provide a link to the ECG phenotype. A variety of mechanisms, including genetic and structural RV alterations, may underlie the Brugada ECG phenotype.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
